| Original language | English (US) |
|---|---|
| Pages (from-to) | 2575-2583 |
| Number of pages | 9 |
| Journal | Journal of the American College of Cardiology |
| Volume | 48 |
| Issue number | 12 |
| DOIs | |
| State | Published - Dec 19 2006 |
Bibliographical note
Funding Information:Dr. Tang serves as a consultant for Medtronic Inc., Boston-Scientific Inc., Neurocrine Biosciences, Otsuka Pharmaceuticals, CV Therapeutics Inc., Amylin Pharmaceuticals, and NovaCardia Inc.; he is a member in the Speakers’ Bureau for Takeda Pharmaceuticals. Dr. Tang also receives research support from the American Heart Association, CV Therapeutics, GlaxoSmithKline Pharmaceuticals, and Abbott Diagnostics Inc. Dr. Francis serves on Scientific Advisory Boards for Pfizer Inc., GlaxoSmithKline Pharmaceuticals, Boehringer-Ingelheim GmbH, Neurocrine Biosciences, and Novartis Pharmaceuticals; he has received research grant support from Pfizer Inc. Dr. Francis also serves as a consultant to Otsuka, and has served on the Data Safety Monitoring Boards for Scios Inc. and Arginox Inc. for their Phase III clinical trials.